Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

28 results about "Iron deficient" patented technology

Iron Deficiency. If the body doesn't absorb its needed amount of iron, it becomes iron deficient. Symptoms appear only when iron deficiency has progressed to iron deficiency anemia, a condition in which the body's iron stores are so low that not enough normal red blood cells can be made to carry oxygen efficiently.

Coding gene for enhancing iron deficiency stress tolerance of plants and application

ActiveCN120718948ABacteriaClimate change adaptationBiotechnologyIron deficient
The invention is applicable to the technical field of bioengineering, and provides a coding gene for enhancing iron deficiency stress tolerance of plants and application. According to the soybean GmMYB14 transcription factor disclosed by the invention, the problem that the growth of soybeans is limited in an iron-deficient environment, particularly calcareous soil and soda saline alkali soil, is solved by excavating and applying the encoding gene (the nucleotide sequence is shown as SEQ ID No.1) of the soybean GmMYB14 transcription factor. Experiments prove that after the gene is over-expressed in arabidopsis thaliana and soybean, the tolerance of plants to iron deficiency stress can be remarkably enhanced. The invention provides a key gene resource for molecular breeding: the GmMYB14 effectively promotes the absorption and utilization of plants on iron by regulating and controlling the metabolic pathway of phenylpropane, not only can improve the planting adaptability of soybeans in low-iron soil, but also can improve the yield and quality of the soybeans, provides powerful technical support for enlarging the planting area of the soybeans in iron-deficient soil regions, and has a wide application prospect. The method is of great significance in relieving insufficient soybean productivity in China and improving the self-sufficiency rate.
Owner:JILIN UNIVERSITY

Maltol iron crystal form DCVIII as well as preparation method and application thereof

The invention discloses a maltol iron crystal form DCVIII, a preparation method and application thereof, a pharmaceutical composition containing the crystal form, and application of the crystal form in preparation of drugs for treating diseases related to iron deficiency of adults. The iron maltol crystal form DCVIII disclosed by the invention has good physical and chemical stability, good humidity stability and relatively low hygroscopicity, provides guarantee for subsequent production and development of medicines, and has relatively high industrial development value.
Owner:BIRDO (SHANGHAI) PHARMATECH CO LTD +4

Pentosicoccus and postbiotic compound thereof for tonifying qi and nourishing face and improving anemia

ActiveCN121086961BBacteriaDigestive systemMicroorganismIron deficient
The application discloses a pentosus pentosaceus and postbiotic compound thereof for tonifying qi, nourishing face and improving anemia, and belongs to the technical field of microbial fermentation. The application screens a pentosus pentosaceus, obtains the bacterial body and postbiotic by culture, and forms a compound of the postbiotic and extract of semen ziziphi spinozae. The compound exhibits a synergistic effect, specifically, compared with the iron deficiency model group, the movement and various blood indexes of rats are improved, and are close to the normal rats of the control group. The indexes of rats in the compound group are better than those of rats fed with probiotics, and rats fed with postbiotic or semen ziziphi spinozae alone, which indicates that the compound can promote the recovery of iron content and protein indexes in the blood of rats more quickly. The application has practical value for comprehensive utilization of the pentosus pentosaceus and postbiotic, and also has important value for tonifying qi, nourishing face and improving anemia.
Owner:胃早安健康科技(山东)有限公司

Application of the PbeARF2 gene, an ARF-like transcription factor from Pyrus pyrifolia

This invention discloses the application of the PbeARF2 gene, an ARF-type transcription factor in *Pyrus pyrifolia*, belonging to the field of bioengineering technology. The nucleotide sequence of the PbeARF2 gene is shown in SEQ ID NO.1. The applications include enhancing plant resistance to iron deficiency stress, promoting root acidification, increasing the activity of ferric reductase under iron deficiency stress, cultivating plant varieties with high resistance to iron deficiency stress, and increasing chlorophyll content in leaves under iron deficiency stress. This invention, through biological experiments, demonstrates for the first time the function of the PbeARF2 ARF-type transcription factor gene and its encoded protein in promoting iron absorption in plants under iron deficiency stress, laying a theoretical foundation for plant variety improvement and the creation of plant varieties with high iron deficiency resistance.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Cyclic iron (II) citrate monohydrate and production method thereof, pharmaceutical and / or nutraceutical and / or food compositions comprising it and uses thereof in therapy and in the nutritional field

PendingAU2024402722A1DiseaseIron deficient
In an iron (II) citrate monohydrate, identified by the formula FeC6H6O7-H2O ( Ferrous citrate monohydrate or iron citrate (II) monohydrate), obtained according to a particular production method, citric acid and elemental iron are bound in a molecular complex where the iron is agglomerated in the citrate which moves to a cyclic form and the iron is bound to the O groups of the carboxylic groups 1 and 3 through ionic bonds, forming two enantiomers, D and L (R and S), both perfectly water-soluble and highly assimilable by the human body. Formula (L) & Formula (D). With a different absorption mechanism from traditional iron molecules, said iron citrate monohydrate is usable in pharmaceutical and / or nutraceutical and / or food compositions, in particular in the treatment and prevention of iron deficiency anemias and in general of all diseases and disorders associated with iron deficiency. The effectiveness is proven by several examples.
Owner:TI FARMA SRL

A gene encoding for enhancing the tolerance of plants to iron deficiency stress and application thereof

The application belongs to the technical field of bioengineering, and provides an encoding gene for enhancing the tolerance of plants to iron deficiency stress and application thereof. The application solves the problem that soybeans are restricted in growth in an iron deficiency environment, especially in calcareous soil and soda saline-alkali soil, by mining and applying the encoding gene (nucleotide sequence as shown in SEQ ID No. 1) of a soybean GmMYB14 transcription factor. Experiments prove that the gene can significantly enhance the tolerance of plants to iron deficiency stress after overexpression in Arabidopsis thaliana and soybeans. The application provides a key gene resource for molecular breeding: GmMYB14 effectively promotes the absorption and utilization of iron in plants by regulating the phenylpropanoid metabolic pathway, which not only can improve the planting adaptability of soybeans in low-iron soil, but also can improve the yield and quality of soybeans, thereby providing strong technical support for expanding the planting area of soybeans in iron deficiency soil areas, and having important significance for relieving the insufficient production capacity of soybeans in China and improving the self-sufficiency rate.
Owner:JILIN UNIVERSITY

Cyclic ferric (ii) citrate monohydrate, process for its production, pharmaceutical and / or nutritional and / or food compositions comprising it and its use in the therapeutic and nutritional field

PendingCN122663115ADiseaseIron deficient
In the ferric iron citrate monohydrate defined by the chemical formula FeC6H6O7 H2O (ferrous citrate monohydrate or ferric iron citrate monohydrate) obtained according to a specific production method, the citric acid and the elemental iron are combined in a molecular complex in which the iron is gathered in the citrate moving into a ring-like form and the iron is bound to the O groups of the carboxyls 1 and 3 through ionic bonds, forming two enantiomers D and L (R and S), both of which are completely water-soluble and highly absorbable by the human body. Formula (L) and Formula (D). With a different absorption mechanism than traditional iron molecules, said ferric iron citrate monohydrate can be used in pharmaceutical compositions and / or nutritional compositions and / or food compositions, in particular for the treatment and prevention of iron deficiency anemia and all diseases and conditions associated with iron deficiency. The effectiveness is demonstrated through several examples.
Owner:TI PHARMACEUTICAL CO LTD

A kit for detecting nutritional iron deficiency in sows and application

The present application relates to a kind of kits for detecting sows' nutritional iron deficiency by biomarker quantitative detection evaluation and application, including fluorescent reaction liquid A, fluorescent reaction liquid B, internal standard, negative control, nucleic acid release agent and quantitative reference product, the fluorescent reaction liquid B contains detection primer and probe, the detection primer includes upstream primer and downstream primer, the sequence of upstream primer is 5'-ATCTGGCTTGTAAACCAACA-3', the sequence of downstream primer is 5'-ATCTTAGTTGTGGATTCCGT-3', the fluorescent reaction liquid B also contains primer probe, probe sequence is 5'-TCACCGTCAATTTCGGCTCT-3', 5' end is labeled with reporter fluorescent group, and 3' end is labeled with quenching fluorescent group.The present application effectively improves the accuracy of sows' nutritional iron deficiency detection, and provides scientific guidance for sow nutrition.
Owner:HUNAN GUOCE BIOTECHNOLOGY CO LTD

A kit for constructing an iron-dependent growth environment for acinetobacter baumannii and a method of use thereof

This invention discloses a kit for constructing an iron-dependent growth environment for Acinetobacter baumannii and its application method, belonging to the field of biotechnology. The kit is specifically designed for Acinetobacter baumannii, and its core components include a 50 mmol / L sterile stock solution tube of 2,2′-bipyridine, a 2000 μmol / L sterile stock solution tube of FeCl3, and a user manual. It does not include general-purpose LB medium, thus avoiding the problem of high-temperature and high-pressure deterioration of core reagents and highlighting the innovative combination of dedicated reagents. This invention also provides the application method of the kit. By adding the kit stock solution to the autoclaved and cooled LB medium in a specific ratio, standardized growth environments with normal iron, iron deficiency, and iron enrichment can be rapidly constructed. Dynamic monitoring and verification of the reversibility of growth inhibition-recovery ensure that the iron environment is precise and controllable. The kit is easy to operate, has good reproducibility, and can achieve standardized construction of the iron environment for Acinetobacter baumannii. It is suitable for iron metabolism-related research such as functional analysis of iron uptake-related proteins, development of iron deprivation antibacterial strategies, and screening of iron-deficient strains.
Owner:HANGZHOU LINAN DISTRICT FIRST PEOPLES HOSPITAL (MEDICAL COMMUNITY OF HANGZHOU LINAN DISTRICT FIRST PEOPLES HOSPITAL)

Recombinant h-ferritin proteins for iron deficiency, iron toxicity and chemotherapy

PendingUS20250388631A1TransferrinsPeptide/protein ingredientsDiseaseIron deficient
The present disclosure includes compositions possessing a recombinant H-ferritin homopolymer that has a plurality of H-ferritin subunits with an amino acid sequence of SEQ ID NO: 1. Methods for treating an iron-related condition in a subject and for treating a neurological or blood disorder in a subject with such compositions are also disclosed.
Owner:THE PENN STATE RES FOUND INC

Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals

The present invention relates to iron complex compounds for subcutaneous use in a method of therapy, e.g., for iron deficiency, particularly of iron deficiency anaemia, in a companion animal and to pharmaceutical compositions for subcutaneous administration, comprising an iron complex compound and a pharmaceutically acceptable carrier. The present invention relates more particularly, although not exclusively, to iron octasaccharide complexes, pharmaceutical compositions comprising an iron octasaccharide complex, and the iron octasaccharide complexes for use in a method of therapy of iron deficiency, particularly of iron deficiency anaemia, in a human or non-human subject.
Owner:PHARMACOSMOS HLDG AS

Rice iron deficiency tolerance gene OsIDT1 and application thereof in improving iron utilization efficiency

The invention discloses application of a rice iron deficiency tolerance gene OsIDT1 (Oryza sativa L. iron deficiency tolerance gene 1). The sequence of the iron-deficiency tolerance gene OsIDT1 is as shown in SEQ ID NO. 1. The gene can be applied in multiple aspects of promoting the iron element to be transferred from mature tissues to new tissues, improving the iron utilization efficiency of the rice and the like. The biological function of the iron-deficiency tolerance gene OsIDT1 in rice is found through a large number of experiments, and the iron element can be prevented from being transferred from a mature tissue to a new tissue by knocking out the gene, so that the iron utilization efficiency, the yield, the grain iron content and the like of the rice are reduced; the over-expression of the gene can promote the iron element to be transferred from mature tissues to new tissues, so that the iron utilization efficiency, the yield, the grain iron content and the like of the rice are improved.
Owner:SANYA INSTITUTE OF NANJING AGRICULTURAL UNIVERSITY

Pediococcus pentosaceus capable of tonifying qi, beautifying face and improving anemia and metagen complex thereof

ActiveCN121086961ABacteriaDigestive systemMicroorganismIron deficient
The invention discloses pediococcus pentosaceus capable of tonifying qi, beautifying skin and improving anemia and a metagen complex thereof, and belongs to the technical field of microbial fermentation. Pediococcus pentosaceus is obtained through screening, thalli and metabiotics of the thalli are obtained through culture, the metabiotics and spina date seed extract form a compound, and the compound shows a synergistic interaction effect, and specifically, compared with an iron-deficiency model group, the movement and various blood indexes of rats are improved, and are close to those of normal rats of a control group. All indexes of rats in the compound group are superior to indexes of corresponding groups of experimental subjects fed with probiotics and independently fed with metabiotics or spina date seeds, and it is indicated that the compound can more quickly promote recovery of the iron content and protein indexes in rat blood. The pediococcus pentosaceus oral liquid has practical value for comprehensive utilization of the pediococcus pentosaceus and the metaplasts thereof, and also has important value in the aspects of tonifying qi, maintaining beauty and improving anemia.
Owner:胃早安健康科技(山东)有限公司

Crystal form dciii of ferric maltol, and preparation method therefor and use thereof

PCT designated stageWO2026067690A1Organic active ingredientsMetabolism disorderSolubilityIron deficient
The present invention relates to crystal form DCIII of compound I and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating iron deficiency-related conditions with or without iron deficiency anemia. The new crystal form of compound I provided by the present invention has the advantages of high solubility, good chemical stability, solid-state stability, mechanical stability and humidity stability, a simple preparation method, easy crystal form control, and a low production scale-up cost, etc., and is of significant value for the future development of the drug.
Owner:BIRDO (SHANGHAI) PHARM R&D CO LTD

Iron compositions and methods of making and using them

Injectable iron compositions comprising iron, a carbohydrate, a stabilizing agent and water are provided. These iron compositions can be prepared by mixing iron with a carbohydrate and water to form a mixture and adding a stabilizing agent to the mixture to form the stable injectable iron composition. These compositions can be considered “ready-to-use” and can treat a variety of diseases, disorders, or conditions characterized by iron deficiency or dysfunctional iron metabolism, for example, anemia.
Owner:VIFOR (INT) AG (SWITZERLAND)

Novel iron and sodium pyrophosphate oral compositions, their preparation methods and their use in iron deficiency states

The present invention relates to novel iron-containing pharmaceutical compositions and / or dietary supplement compositions and / or food compositions, and their use in the treatment and / or prevention of absolute or relative iron deficiency conditions in subjects in need thereof. Specifically, the present invention relates to novel compositions containing highly assimilable iron, and their use in the treatment and / or prevention of disorders and diseases associated with iron deficiency. The present invention also relates to methods for preparing said compositions.
Owner:PHARMANUTRA SPA

Strain for significantly improving yield of hsa f under iron limitation condition and application thereof

ActiveCN116103214BImprove synthesis abilityIncrease productionBacteriaMicroorganism based processesIron deficientNucleotide
The application discloses a strain for significantly improving HSAF yield under iron limitation and application thereof, and the genetically engineered bacterium is obtained by knocking out or silencing an iron response transcription factor Fur gene of L.enzymogenes OH11, and the nucleotide sequence of the Fur gene is shown as SEQ ID NO.1.Compared with a wild type strain, the mutant strain has no significant difference in growth in an iron deficiency or low-iron culture medium, and the HSAF synthesis capacity is greatly improved.The HSAF yield of the mutant strain in the iron deficiency culture medium reaches 162.34+5.84 mg / L, which is 3.60 times of that of the wild type strain.Therefore, the technical scheme of the application provides a more direct and effective way for improving the HSAF yield of L.enzymogenes OH11 in the iron deficiency or low-iron environment.
Owner:JIANGSU ACAD OF AGRI SCI

Lactobacillus reuteri detection primer, kit and application

The application belongs to the technical field of detection, and particularly relates to a primer and kit for detecting lactobacillus reuteri and application, which comprises an upstream primer and a downstream primer, the sequence of the upstream primer is 5'-AAGCACCCTGATCCGCAAT-3', and the sequence of the downstream primer is 5'-AATTTGCCGCGCTTCGTCT-3'. The application has high sensitivity, good specificity and high precision, and can effectively detect early nutritional iron deficiency of sows.
Owner:HUNAN GUOCE BIOTECHNOLOGY CO LTD

Novel iron and acacia gum oral compositions, their preparation methods and their use in iron deficiency conditions

The present invention relates to novel iron-containing pharmaceutical and / or nutraceutical and / or food compositions, and their use in the treatment and / or prevention of absolute or relative iron deficiency conditions in individuals in need thereof. Specifically, the present invention relates to novel compositions containing highly assimilable iron, and their use in the treatment and / or prevention of disorders and conditions associated with iron deficiency. The present invention also relates to methods for preparing said compositions.
Owner:PHARMANUTRA SPA

Hydroxyproline preparation for improving iron deficiency tolerance of plants

The invention discloses a hydroxyproline preparation for improving iron deficiency tolerance of plants, and belongs to the technical field of plant physiology and agricultural biology. The hydroxyproline preparation is a hydroxyproline aqueous solution with the mass volume concentration of 0.65 mg / L and is used for improving the tolerance of plants to iron deficiency stress. Specifically, a hydroxyproline preparation is added into a plant culture medium or the hydroxyproline preparation is irrigated into soil, so that the fresh weight, chlorophyll content and the like of the plant can be remarkably improved, and the tolerance of the plant to iron deficiency stress is improved. The method is suitable for crop cultivation in an iron-deficient soil environment, has the advantages of low cost, environmental friendliness, simplicity and convenience in operation and the like, can replace traditional iron fertilizers, reduces the risk of heavy metal pollution in agricultural production, and provides a new scheme and technical support for iron-deficient stress-resistant breeding of crops.
Owner:HEFEI UNIV OF TECH

Portable blood iron metabolism index rapid detection microfluidic sensor method

InactiveCN121208318ABiological testingMaterial capacitanceTransferrin ironIron deficient
The invention discloses a portable blood iron metabolism index rapid detection micro-fluidic sensor method, and relates to the field of index detection, and the method comprises the following steps: detecting device module composition, designing a wearing housing, configuring a capacitive attachment state detection module and a determination mechanism, configuring a state indication module initialization state feedback mechanism and sampling preparation state. By constructing a portable detection structure integrating microneedle sampling, micro-fluidic guiding, iron metabolism index identification, signal conditioning and data processing and graphical interactive feedback, accurate identification and quantitative analysis of four iron metabolism core indexes including ferritin, transferrin, heme and Fe < 2 + > are realized; the collection and index judgment of the blood sample can be quickly completed on the premise that the support of large laboratory equipment is not needed; according to the method, an iron metabolism classification mechanism based on concentration ratio calculation and weight correction judgment is introduced, and the capacity of automatically recognizing storage iron deficiency, functional iron deficiency, iron load excess and other states is achieved.
Owner:DONGTAI PEOPLES HOSPITAL

Veterinary composition for controlling iron deficiency in non-human mammals and its use

The present invention relates to veterinary compositions comprising an iron complex and a water-soluble polymer as the only active ingredients. The present invention further relates to the use of such compositions for controlling iron deficiency and / or anemic conditions in non-human mammals.
Owner:セヴァサンテアニマレ

Methods for treating iron deficiency-related diseases

PendingJP2026506600AFungiNervous disorderDiseaseIron deficient
Anemia, defined as a reduction in the amount of functional red blood cells in circulation, is a major cause of disease affecting one-third of the world's population. Iron is essential for hemoglobin, the functional component of red blood cells, to store and transport oxygen. Hepcidin, a liver-derived peptide, is a key regulator of iron homeostasis. During anemia, the erythropoietic hormone erythroferon regulates hepcidin synthesis to ensure an adequate supply of iron to the bone marrow for red blood cell synthesis. However, accumulating evidence suggests that other factors may perform a similar function. We identified the hepatokine FGL1 as a previously undescribed hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent hepcidin suppressor in vitro and in vivo. Deletion of Fgl1 in mice blunts hepcidin suppression after hemorrhage.Finally, FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the BMP-SMAD signaling cascade that controls hepcidin regulation.Therefore, the present invention relates to an FGL1 polypeptide for use in treating patients suffering from iron deficiency-related diseases.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Functional compositions, conditioners and use thereof in the preparation of supplements for improving sub-health of the body

PendingCN122321031ABiotechnologyIron deficient
This application discloses a functional composition, a conditioning agent, and its application in the preparation of a supplement for improving sub-health conditions. The functional composition comprises a first active ingredient and a second active ingredient. The first active ingredient includes red raspberry and carrot, and the second active ingredient includes one or more of artichoke extract and Fusarium oxysporin. The mass ratio of the first active ingredient to the second active ingredient is (1-10000):(1-10000). This application, through the formulation of active ingredients, promotes the body's absorption of iron through mechanisms such as intestinal iron absorption and / or regulation of hepcidin, thereby supplementing iron and significantly improving iron deficiency. Therefore, the functional composition provided by this application can be used to improve symptoms such as anemia caused by functional iron deficiency. Simultaneously, the functional composition also has beneficial effects such as regulating constitution, replenishing qi and blood, and improving sub-health conditions.
Owner:BEIJING QINGYAN BOSHI HEALTH MANAGEMENT CO LTD +1

Use of cinnamyl aldehyde in preparation of drugs for improving iron deficiency anemia and adverse pregnancy outcomes of pregnant women during pregnancy

ActiveCN119745844BAldehyde active ingredientsSexual disorderIron deficientFetal growth
The application discloses application of cinnamyl aldehyde in preparation of a medicine for improving iron deficiency anemia and adverse pregnancy outcomes of pregnant women during pregnancy, and after treatment with the cinnamyl aldehyde, anemia symptoms of the pregnant women caused by iron deficiency during pregnancy can be significantly relieved, and adverse pregnancy outcomes caused by iron deficiency anemia can also be relieved, and the specific performance is relieving fetal growth restriction, thereby providing a new medicine and treatment selection for treating iron deficiency anemia and improving adverse pregnancy outcomes of the pregnant women during pregnancy.
Owner:SOUTHERN MEDICAL UNIVERSITY